From Relapse to Remission: Mapping the Treatment Journey in Adult R/R-Cell ALL - Part 2

Speciality: Oncology

Description:

We’re pleased to welcome you to the second installment of our focused series on adult relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-Cell ALL). This session, introduced by Dr. Nitin, Dr. Riyaz, and Dr. Eesha, aims to provide deeper insight into the evolving strategies for managing high-risk patients. With decades of combined experience in hematologic malignancies, our panel brings real-world expertise and evidence-based perspectives to this crucial discussion.

Today’s session explores optimal first-salvage therapy in patients presenting with a high disease burden - one of the most challenging scenarios in adult B-cell ALL management. From chemotherapy-resistant disease to immunotherapeutic breakthroughs, we’ll cover cutting-edge approaches including monoclonal antibodies, BiTEs, and CAR T-cell therapy. The emphasis is on tailoring treatment strategies that offer the best chance at remission while considering patient-specific factors such as prior therapies, tumor load, and performance status.

We sincerely thank you for joining us in this educational journey. Your engagement reflects a shared commitment to improving outcomes for adult ALL patients. Special thanks to our expert faculty for their insights, and to the clinical teams who continue to push the boundaries of care. Together, we move closer to transforming relapse into remission.

See More Webinars @ Hidoc Webinars